Persistent Pulmonary Hypertension Among Infants Undergoing Therapeutic Hypothermia for Hypoxic Ischemic

Rashida Javed1, Tim J Van Hasselt2, Narasimha Rao3

  • 1Department of Paediatrics, Northampton General Hospital, Northampton, UK.

Insights

Therapeutic hypothermia (TH) did not show an association with persistent pulmonary hypertension (PPHN) in infants with hypoxic-ischemic encephalopathy (HIE). Clinicians should remain vigilant for PPHN in both TH and non-TH groups.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Critical Care Medicine

Background:

  • Persistent pulmonary hypertension (PPHN) is a serious condition in neonates.
  • Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal mortality and morbidity.
  • Therapeutic hypothermia (TH) is a standard treatment for moderate to severe HIE.

Purpose of the Study:

  • To systematically review and meta-analyze the association between PPHN and TH in infants with moderate to severe HIE.
  • To compare the incidence of PPHN in infants receiving TH versus those not receiving TH.

Main Methods:

  • Systematic review and meta-analysis of randomized control trials (RCTs) from 2000 to 2025.
  • Searches conducted in Ovid, Medline, Embase, and Cochrane Central databases.
  • Seven RCTs involving 1006 infants were included in the meta-analysis for PPHN outcomes.

Main Results:

  • The relative risk of PPHN for TH versus non-TH (NT) was 1.13 (95% CI 0.81 to 1.57).
  • No statistically significant association was found between TH and PPHN.
  • A considerable number of infants developed PPHN in both TH and NT groups, with noted risk of bias in participant blinding.

Conclusions:

  • Current evidence does not support an association between therapeutic hypothermia and an increased risk of persistent pulmonary hypertension in infants with moderate to severe HIE.
  • Clinicians should maintain awareness of PPHN risk and ensure prompt investigation and management for all infants with HIE, regardless of TH status.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
318
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
360
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
285